TRex Bio Inc. (TRXB:NASDAQ) closed at $13.64 on November 2, 2026, down 0.73% on the day. The stock trades 17.6% below its 52-week high of $16.56 and 4.1% above its 52-week low of $13.10. Over the past year, it lost 2.6%. TRex Bio Inc. is part of the Health Care sector.
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio's Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio's wholly owned pipeline and through collaborations with leading pharmaceutical partners. TRexBio is led by an experienced management team and headquartered in South San Francisco, California.
Find more stocks like TRXB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.